Clinical Trial: Ranibizumab for the Inhibition of Neovascularization in Pterygia

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Ranibizumab for the Inhibition of Neovascularization in Pterygia

Brief Summary: The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery.

Detailed Summary: As a secondary objective, this study also aims to establish the tissue concentration of ranibizumab when delivered via subconjunctival injection in patients undergoing pterygium excision and to determine the effects of ranibizumab on conjunctival healing, corneal epithelial healing, and wound dehiscence.
Sponsor: Bascom Palmer Eye Institute

Current Primary Outcome: The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery. [ Time Frame: 2 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome: This study aims to establish the tissue concentration of ranibizumab when delivered via subconjunctival injection and determine the effects of ranibizumab on conjunctival healing, corneal epithelial healing, and wound dehiscence. [ Time Frame: 2 years ]

Original Secondary Outcome: Same as current

Information By: Bascom Palmer Eye Institute

Dates:
Date Received: October 7, 2008
Date Started: October 2008
Date Completion:
Last Updated: July 24, 2012
Last Verified: July 2012